http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Soligenix receives EU orphan drug status for Behçet's disease treatment
-
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
-
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
-
Soligenix Announces HyBryte™ Clinical Summary Published in "Expert Opinion on Investigational Drugs"
-
Soligenix receives UK medicine designation for Behcet's disease drug
-
Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
-
SOLIGENIX receives positive EMA opinion for SGX945 orphan drug designation
-
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
-
Soligenix to Present at BIO Investment & Growth Summit
-
Soligenix publishes phase 2 trial results for SGX945 in Behçet's disease
-
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
-
Soligenix reports phase 2a psoriasis trial results for SGX302
-
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
-
Soligenix hits enrollment target for HyBryte lymphoma trial interim analysis
-
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
-
Soligenix updates medical advisory board for lymphoma drug development
-
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
-
Soligenix reports positive safety review for phase 3 CTCL trial
-
Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
-
Soligenix expands European medical board for lymphoma drug approval push
-
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
-
Soligenix completes $7.5 million public offering with warrants
-
Soligenix Announces Closing of $7.5 Million Public Offering
-
Soligenix prices $7.5 million public offering at $1.35 per share
-
Soligenix Announces Pricing of $7.5 Million Public Offering
-
Soligenix names former White House adviser Philipson as strategic advisor
-
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
-
Soligenix vaccine study shows 2-year stability at high temperatures
-
Soligenix Announces Publication Describing Long-Term High Temperature Stability of Protein Subunit Vaccines for Ebola and Related Viruses
-
Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference
-
Soligenix receives FDA orphan drug designation for Behçet's disease
-
FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
-
Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
-
Soligenix SGX945 shows efficacy in Behçet's disease phase 2 trial
-
Soligenix reports positive phase 2 trial results for Behçet's disease drug
-
Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease
-
Soligenix (SNGX) Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
-
Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
-
Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
-
Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
-
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks
-
Soligenix, Inc. (SNGX) Announces Publication Demonstrating CiVax Booster Induces Rapid Broad Protection Against COVID-19 Variants
-
Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants
-
Soligenix (SNGX) Provides Update on Recent Accomplishments, Reports FY24 Results
-
Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results
-
HyBryte™ Treatment Studies Presented at Two Medical Conferences in March
-
Soligenix to Present at BIO CEO & Investor Conference
-
Soligenix to Present at Upcoming Investor Conferences
-
HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
